A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

Trial Details

NCT ID
NCT05753722
Phase
PHASE1
Sponsor
Incendia Therapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • PRTH-101
  • Pembrolizumab
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Portland, Oregon, United States|45.52345,-122.67621
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Subject must be willing and able to read, understand, and sign an Informed Consent Form.
  • Subject must be age ≥18 years.
  • Subject has metastatic or advanced, unresectable malignancy and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 a…
  • Subject has a pathologically documented advanced/unresectable or metastatic cancer that is refractory to or intolerable to or the subject is unwill…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →